U.S. Implantable Medical Devices Market Analysis & Forecast: 2025-2032

U.S. Implantable Medical Devices Market Analysis & Forecast - 2025 to 2032

U.S. Implantable Medical Devices Market is estimated to be valued at USD 21.7 Bn in 2025 and is expected to reach USD 32.84 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 6.1% from 2025 to 2032. 

Key Takeaways

• By Implant Type, the orthopaedic implants segment is projected to lead the U.S. implantable medical devices market, accounting for a 29.8% share in 2025. This dominance is driven by the high prevalence of musculoskeletal disorders, sports injuries, and an aging population prone to joint degeneration.
• By End User, the Hospitals are expected to capture a leading 59.8% share of the U.S. implantable medical devices market in 2025.

Market Overview

The U.S. Implantable Medical Devices Market is witnessing robust growth, driven by the rising prevalence of chronic diseases, technological advancements, and an aging population. Implant types such as orthopaedic, cardiovascular, and neurostimulators are in high demand due to increasing surgical procedures and improved clinical outcomes. Orthopaedic implants lead the segment, fuelled by joint replacement and trauma-related surgeries.

Current Events and its Impacts on the U.S. Implantable Medical Devices Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

U.S. Implantable Medical Devices Market Trends

• Escalating Prevalence of Heart Diseases Propels Industry Growth

The industry is witnessing significant growth driven by the rising occurrence of various disorders in cardiovascular, ophthalmology, orthopaedic, plastic surgery, dental, and neurology fields. Among these, heart diseases, including cardiovascular disease (CVD), congenital heart defects (CHDs), and stroke, emerge as the primary cause of global mortalities.

According to the World Health Organization (WHO), approximately 17.9 million deaths occur each year due to these heart conditions, accounting for around 31% of all global fatalities. Notably, CHD affects around 7.4 million individuals, while stroke claims the lives of approximately 6.7 million people annually.

Projections suggest that by 2030, CVDs will be responsible for an estimated 23.6 million deaths worldwide. Unhealthy dietary habits, excessive alcohol and tobacco consumption, and sedentary lifestyles are major contributing factors to the increasing incidence and prevalence of heart diseases. With the continued upward trend in these conditions, there exists a significant market opportunity for future growth.

In August 2024, Reuters reported that Zimmer Biomet exceeded profit expectations in Q2 as demand for hip and knee implants surged. The company also acquired AI-driven guidance firm OrthoGrid Systems to enhance surgical precision.

• Technical advancement in implantable devices

Manufacturers are focused on technological advances in implantable devices by adopting nanotechnology as the future of their products which expected to drive the growth of the U.S. Implantable medical devices market in near future. The advancements in this field will greatly improve the effectiveness of implantable devices.

By successfully launching technologically advanced products early, manufacturers can secure a significant market share and become leaders in the market. For instance, in December 2025, Abbott, a multinational medical devices and health care company, announced the U.S. Food and Drug Administration (FDA) approval of the company's Eterna spinal cord stimulation (SCS) system– the smallest implantable device, rechargeable spinal cord stimulator currently available on the market for the treatment of chronic pain.

Eterna SCS utilizes Abbott's proprietary low-dose BurstDR stimulation, the only SCS waveform technology with the highest level of clinical evidence (1A evidence), proven to reduce pain 23% more than traditional waveform technology approaches. In May 2025, Reuters reported that the FDA granted “breakthrough device” designation to Neuralink’s brain-computer interface implant, aimed at restoring speech for individuals with paralysis—a regulatory milestone likely to accelerate development and potential approval.

Segmental Insights 

To learn more about this report, Download Free Sample

U.S. Implantable Medical Device Market Insights, By End User

The hospitals segment is expected to capture a dominant 59.8% share of the U.S. implantable medical devices market in 2025, owing to their central role in conducting complex surgical implant procedures. Equipped with specialized infrastructure, advanced diagnostics imaging services, and highly trained surgical teams, hospitals remain the preferred setting for orthopaedic, cardiovascular, and neurological implantations.

Additionally, hospitals benefit from favourable reimbursement frameworks and increasing adoption of robotic-assisted surgeries, which enhance procedural precision and patient outcomes. The rise in chronic conditions and age-related degenerative diseases is further boosting surgical volumes in hospital settings, solidifying their leading position in the implantable devices ecosystem.

U.S. Implantable Medical Device Market Insights, By Implant Type

Orthopaedic implants are projected to account for a leading 29.8% share of the U.S. implantable medical devices market in 2025. This segment's growth is fuelled by the aging population, increasing incidence of osteoarthritis, and higher demand for joint reconstruction and spinal implants. Advancements in biomaterials, 3D printing, and minimally invasive surgical techniques are enhancing implant performance, durability, and patient satisfaction.

The rise in sports-related injuries and trauma cases has also contributed to the expanding orthopaedic implant market. With continuous innovation and growing patient preference for improved mobility solutions, orthopaedic implants are set to maintain a strong foothold in the overall implantable devices landscape.

Market Report Scope

Analyst Viewpoint – U.S. Implantable Medical Devices Market

• The continuous shift toward minimally invasive procedures and next-generation implant technologies is reshaping patient care and expanding the market's scope.
• Experts highlight increasing physician preference for smart and bio-integrated implants, including pacemakers, spinal cord stimulators, and joint replacements enhanced with sensors or drug-eluting properties. This shift is improving long-term patient outcomes, reducing recovery times, and supporting the adoption of personalized medicine approaches.
• Regionally, the U.S. leads the global implantable medical devices landscape due to a well-established healthcare infrastructure, favorable reimbursement policies, and strong R&D capabilities. The presence of major MedTech companies and robust clinical trial pipelines further reinforces the country’s dominance.
• Looking ahead, analysts believe innovation in AI-guided surgeries, 3D-printed custom implants, and biocompatible materials will drive the next phase of market growth and enhance healthcare delivery efficiency.

U.S. Implantable medical devices Market: Key Development

• In April 2025, the U.S. FDA granted approval for the WiSE system, the first-ever leadless left ventricular endocardial pacing (LVEP) solution for cardiac resynchronization therapy, marking a breakthrough in heart failure treatment. Enables treatment of patients previously unsuitable for conventional CRT due to vascular anatomy or lead complications, significantly expanding the target population and reinforcing the market’s shift toward leadless cardiac devices.
• In February 2025, Medtronic acquired innovative nano-surface technology and related IP from Nanovis, aimed at enhancing PEEK interbody fusion implants used in spine surgery. Incorporation of osseointegrative surface tech boosts implant fixation and clinical outcomes, strengthening Medtronic’s spine portfolio and elevating its competitive edge in orthopaedic implantable devices.
• In March 2025, Leading medical device companies are acquiring firms with AI, robotics, and digital health capabilities such as Medtronic’s purchase of Nanovis tech and Boston Scientific’s acquisition of Sonivie focusing on smart and minimally invasive implantable solutions. These strategic moves accelerate integration of AI and precision tech into implant design, expand product portfolios, and optimize long-term product pipelines in U.S. medtech markets.
• In April 2024, the FDA granted premarket approval for Medtronic's Inceptiv™ closed-loop spinal cord stimulation system, designed to dynamically adjust therapy based on patient feedback. Offers real-time adaptive neuromodulation, improving pain management and patient outcomes while setting a higher standard for implantable neurostimulation devices.
• In November 2024, Johnson & Johnson acquired Shockwave Medical specialists in coronary and peripheral lithotripsy for $13.1 billion, boosting its interventional cardiology implant device portfolio. This mega-deal strengthens J&J’s position in cardiovascular markets, facilitating synergies with existing implantable technologies and catalysing future growth in procedural innovation.

Market Segmentation

• U.S. Implantable Medical Devices Market, By Implant Type
• Orthopedic Implants
• Cardiovascular implants
• Dental Implants
• Intraocular Lens Implants
• Breast Implants
• Others
• U.S. Implantable Medical Devices Market, By End User
• Hospitals
• Clinics
• Others
• Company Profiles
• Abbott Laboratories
• Alcon Laboratories
• Biomet Incorporated
• Bausch and Lomb Incorporated
• Boston Scientific Corporation
• Johnson and Johnson
• Medtronic Plc
• St. Jude Medical Incorporated
• Smith and Nephew PLC
• Stryker Corporation
• Synthes Incorporated
• Zimmer Holdings Incorporated

Sources

The Stakeholders Consulted

• Hospital administrators and procurement managers
• Surgeons and interventional specialists (orthopedic, cardiovascular, neurological)
• Medical device manufacturers and implant designers
• Regulatory compliance experts (FDA, CMS)
• Clinical researchers and bioengineers specializing in implantable technologies
• Health insurance and reimbursement policy advisors
• Healthcare consultants focused on surgical technology adoption
• Private clinics and outpatient surgical centers
• Public and private health system executives

Databases Opened

• U.S. Food and Drug Administration (FDA) – Medical Devices Database
• Centers for Medicare & Medicaid Services (CMS) – Reimbursement Data
• National Institutes of Health (NIH) – Clinical Trials and Biomedical Innovation Reports
• U.S. Census Bureau – Healthcare Utilization & Demographics
• World Bank Open Data – U.S. Healthcare Expenditure Statistics

Magazines & Trade Publications

• MedTech Dive
• Medical Device & Diagnostic Industry (MD+DI)
• BioWorld MedTech
• Today's Medical Developments
• Medical Design & Outsourcing
• Becker’s Hospital Review – Surgery and Devices Section

Scientific and Industry Journals

• Journal of Biomedical Materials Research
• The Journal of Arthroplasty
• Journal of Cardiovascular Electrophysiology
• Neuromodulation Technology at the Neural Interface
• Annals of Biomedical Engineering

Newspapers & Media Outlets

• The Wall Street Journal – Health & Technology
• Bloomberg – U.S. Healthcare and MedTech Sector
• Reuters Health News – U.S. Medical Devices Coverage
• The New York Times – Science & Medicine
• FierceBiotech and FierceMedTech

Associations and Regulatory Bodies

• U.S. Food and Drug Administration (FDA) – Center for Devices and Radiological Health (CDRH)
• Centers for Medicare & Medicaid Services (CMS)
• American Academy of Orthopaedic Surgeons (AAOS)
• American College of Cardiology (ACC)
• AdvaMed (Advanced Medical Technology Association)

Public Domain Sources

• U.S. National Library of Medicine – ClinicalTrials.gov
• U.S. Department of Health & Human Services – Health System Data
• Congressional Budget Office (CBO) – Medical Spending Trends
• National Center for Health Statistics (NCHS)
• U.S. Bureau of Economic Analysis – Healthcare Device Sector

Proprietary Research Elements

• CMI Data Analytics Tool
• Proprietary CMI Repository of Market Data (covering past 8 years)
• CMI Expert Interviews and Transcripts (focused on surgical trends, reimbursement scenarios, and implant innovation across the U.S.)